

# PrEP, Health Disparities, and Future Directions

**Patrick Sullivan, DVM, PhD**  
**Rollins School of Public Health, Emory University**


**September 29<sup>th</sup>, 2016**



# Presentation Plan

- Health disparities
- Scaling prevention tools for MSM: what do we know?
- The PrEP Continuum
- PrEP Uptake
- HealthMindr: A comprehensive prevention app for MSM
- PrEP@Home

# Rates of Persons Living with an HIV Diagnosis, by County, 2012



Data not shown \*   
Data not released to AIDSvu \*\*

\* Data are not shown to protect privacy. \*\* State health department requested not to release data.

Note. Data include persons with a diagnosis of HIV infection, regardless of the stage of disease at diagnosis, and have been statistically adjusted to account for reporting delays and missing risk-factor information, but not for incomplete reporting.

Data Source: Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention.



# HIV Prevalence Disparities by Race/Ethnicity, Chicago, 2013

## Estimated HIV Prevalence Rate Ratios by Race/Ethnicity, 2013



The rate of black males living with an HIV diagnosis is 1.8 times that of white males.



The rate of Hispanic/Latino males living with an HIV diagnosis is 0.8 times that of white males.




The rate of black females living with an HIV diagnosis is 11.0 times that of white females.




The rate of Hispanic/Latina females living with an HIV diagnosis is 3.0 times that of white females.



# Rates of New HIV Diagnoses, Chicago, 2010-2014



Chicago - Number of Persons Newly Diagnosed with HIV, 2010-2014




\*Data not shown to protect privacy because of a small number of cases and/or a small population.

\*\*Data not available.


NOTE: Data represent persons newly diagnosed with HIV or AIDS in the City of Chicago between 2010 and 2014 and who were entered as of 02/28/2016. Cases are based on residence at diagnosis. Data have not been adjusted for reporting delays. See Data Methods for more information.

DATA NOT SHOWN \*   
DATA NOT AVAILABLE \*\*


# Rates of New HIV Diagnoses, by Race, Chicago, 2010-2014



White, non-Hispanic



Black, non-Hispanic



Hispanic

Chicago - Number of White Persons Newly Diagnosed with HIV, 2010-2014




\*Data not shown to protect privacy because of a small number of cases and/or a small population.

\*\*Data not available.

NOTE: Data represent persons newly diagnosed with HIV or AIDS in the City of Chicago between 2010 and 2014 and who were entered as of 02/28/2016. Cases are based on residence at diagnosis. Data have not been adjusted for reporting delays. A SeeA Data Methods for more information.


DATA NOT SHOWN \*   
DATA NOT AVAILABLE \*\* 

# Percent of men who are MSM among population and people living with HIV/AIDS, United States and Chicago, 2014



## Sources:


1. Purcell et al 2012; The Open AIDS Journal, 2012, 6, (Suppl 1: M6) 98-107.
2. Grey et al 2016; JMIR Public Health Surveill 2016;2(1):e14
3. Chicago Department of Public Health. HIV/STI Surveillance Report, 2015. Chicago, IL: City of Chicago; December 2015.
4. Centers for Disease Control and Prevention. HIV Surveillance Report, 2014; vol. 26. <http://www.cdc.gov/hiv/library/reports/surveillance/>. Published November 2015.



Mayer et al. *Curr Opin HIVAIDS*, 2015, modified from Abdool Karim et al, *AVAC Report*, 2014

# PrEP works, but adherence is key

## → Effectiveness and Adherence in Trials of Oral and Topical Tenofovir-Based Prevention




Trials of oral and topical tenofovir-based PrEP show that these strategies reduce risk of HIV infection if they are used correctly and consistently. Higher adherence is directly linked to greater levels of protection.

Source: Salim S. Abdool Karim, CAPRISA


“Drugs don’t work in patients who don’t take them.”

- C. Everett Koop

# Scale of HIV Prevention Interventions for MSM: What Do We Know?




## Estimated percent of new HIV infections among MSM prevented by three prevention approaches, four countries



Source: Sullivan et al, Lancet 2012

# Cumulative proportion of infections among MSM averted by early implementation of antiretroviral therapy for MSM living with HIV infection period at 4 levels of coverage in 4 countries




Source: Sullivan et al, Lancet 2012

# Estimated percent of new HIV infections among MSM prevented by oral PrEP at varying levels of adherence, four countries




HIV infections estimated to be averted by PrEP, reduction in UAI, and early ARV treatment in a stochastic simulation model of HIV transmissions among MSM in Africa




Source: Brookmeyer et al, PLoS ONE 2014

HIV infections estimated to be averted by PrEP, reduction in UAI, increased HIV testing, and early ARV treatment in a stochastic simulation model of HIV transmissions among MSM in Africa



Source: Brookmeyer et al, PLoS ONE 2014

# PrEP Coverage, Adherence, and Impact




Jenness et al, J Infect Dis 2016, in press



To make modest impacts on  
HIV transmissions among  
MSM, we will need to  
achieve 30-50% coverage of  
multiple interventions

So how are we doing?


**Fig. 1** Estimated coverage of primary HIV prevention interventions among men who have sex with men in the USA and estimated levels of coverage required to reduce HIV incidence, 2010–2015. *NHBS* National HIV Behavioral Surveillance, *AMIS* American Men’s Internet Survey, *KFF* Kaiser Family Foundation, *NR* not reported, *PrEP* preexposure prophylaxis, *nPEP* nonoccupational postexposure prophylaxis. *Shaded area* represents the coverage of multiple primary HIV prevention interventions estimated by models to result in meaningful (i.e., 25–30 %) reductions in HIV incidence among MSM



[https://jebjones.shinyapps.io/intervention\\_coverage](https://jebjones.shinyapps.io/intervention_coverage)



# Use of PrEP by year, US MSM, 2012-2016




## Sources:

1. Centers for Disease Control and Prevention. A web-based survey of HIV testing and risk behaviors among gay, bisexual, and other men who have sex with men—United States, 2012. HIV Surveillance Special Report 14. Revised edition. <http://www.cdc.gov/hiv/library/reports/surveillance/#panel2>. Published March 2016.
2. Sanchez et al 2015; JMIR Public Health Surveill 2015;1(1):e3
3. Sanchez et al 2016; JMIR Public Health Surveill 2016;2(1):e2




# Diagnoses of HIV Infection among Men Who Have Sex with Men, by Age Group, 2010–2014—United States and 6 Dependent Areas



*Note.* Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been statistically adjusted to account for reporting delays and missing transmission category, but not for incomplete reporting. Data on men who have sex with men do not include men with HIV infection attributed to male-to-male sexual contact *and* injection drug use.



## Awareness of PrEP by age, 7003 US MSM, 2013-2015




### Sources:

1. Sanchez et al 2015; JMIR Public Health Surveill 2015;1(1):e3
2. Sanchez et al 2016; JMIR Public Health Surveill 2016;2(1):e2



# Willingness to use PrEP by age, 6760 US MSM, 2013-2015




## Sources:

1. Sanchez et al 2015; JMIR Public Health Surveill 2015;1(1):e3
2. Sanchez et al 2016; JMIR Public Health Surveill 2016;2(1):e2



# Use of PrEP by age, 6864 US MSM, 2013-2015



## Sources:

1. Sanchez et al 2015; JMIR Public Health Surveill 2015;1(1):e3
2. Sanchez et al 2016; JMIR Public Health Surveill 2016;2(1):e2



# The PrEP Continuum

HIV/AIDS

VIEWPOINTS

## Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia

**Colleen F. Kelley,<sup>1,2</sup> Erin Kahle,<sup>2</sup> Aaron Siegler,<sup>2</sup> Travis Sanchez,<sup>2</sup> Carlos del Rio,<sup>1,3</sup> Patrick S. Sullivan,<sup>2</sup> and Eli S. Rosenberg<sup>2</sup>**

<sup>1</sup>Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, <sup>2</sup>Department of Epidemiology, and <sup>3</sup>Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia

---

**(See the Editorial Commentary by Mayer and Krakower on pages 1598–600.)**

**Reductions in human immunodeficiency virus (HIV) incidence with pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) will require significant coverage of those at risk. We propose a simplified frame-**




# Theoretical model of the PrEP care continuum, factors relevant to uptake, and areas for intervention.

	Factors Relevant to PrEP Uptake	Interventions to Enhance PrEP Uptake
Awareness/ willingness	<ul style="list-style-type: none"> <li>• Awareness of PrEP</li> <li>• Risk/benefit perceptions</li> <li>• Barriers to seeking PrEP                             <ul style="list-style-type: none"> <li>• PrEP cost</li> <li>• PrEP side-effects</li> <li>• Perceived PrEP stigma</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Mass media campaigns</li> <li>• Community mobilization</li> <li>• Alternative PrEP formulations</li> <li>• Community-based efforts to destigmatize PrEP</li> </ul>
Access to Healthcare	<ul style="list-style-type: none"> <li>• Individual                             <ul style="list-style-type: none"> <li>• Has public or private health insurance</li> <li>• Regularly sees primary care doctor</li> <li>• Can afford medication</li> <li>• Transportation</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Medication and/or co-payment waivers</li> <li>• Free service provision</li> <li>• Enhanced access                             <ul style="list-style-type: none"> <li>• Centralized provision</li> <li>• Enhanced referral systems</li> </ul> </li> </ul>
Likely to Receive Rx	<ul style="list-style-type: none"> <li>• Healthcare provider                             <ul style="list-style-type: none"> <li>• Aware of PrEP</li> <li>• Willing to prescribe PrEP</li> <li>• Screens for risk and determines patient eligible</li> </ul> </li> <li>• Patient                             <ul style="list-style-type: none"> <li>• Adequately report behavior eligible for PrEP</li> <li>• PrEP not contraindicated</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Provider education/training</li> <li>• Electronic tools to assess sexual risk and indicate PrEP</li> <li>• Automated systems to minimize provider burden</li> </ul>
Adherence and Efficacy	<ul style="list-style-type: none"> <li>• Side-effects/medication tolerance</li> <li>• Risk compensation</li> <li>• Dosing schedules</li> <li>• Long-term adherence and PrEP continuation</li> </ul>	<ul style="list-style-type: none"> <li>• Counseling                             <ul style="list-style-type: none"> <li>• Medication adherence</li> <li>• Sexual risk reduction</li> </ul> </li> <li>• Home support systems to minimize patient testing burden</li> <li>• Electronic adherence reminders/support</li> </ul>

Colleen F. Kelley et al. Clin Infect Dis. 2015;61:1590-1597



# The PrEP care continuum for (A) the total Involvement cohort, (B) black MSM (C) white MSM and (D) HIV seroconverters in the Involvement cohort.



Colleen F. Kelley et al. Clin Infect Dis. 2015;61:1590-1597



# Theoretical model of the PrEP care continuum, factors relevant to uptake, and areas for intervention.

	Factors Relevant to PrEP Uptake	Interventions to Enhance PrEP Uptake
Awareness/ willingness	<ul style="list-style-type: none"> <li>• Awareness of PrEP</li> <li>• Risk/benefit perceptions</li> <li>• Barriers to seeking PrEP                             <ul style="list-style-type: none"> <li>• PrEP cost</li> <li>• PrEP side-effects</li> <li>• Perceived PrEP stigma</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Mass media campaigns</li> <li>• Community mobilization</li> <li>• Alternative PrEP formulations</li> <li>• Community-based efforts to destigmatize PrEP</li> </ul>
Access to Healthcare	<ul style="list-style-type: none"> <li>• Individual                             <ul style="list-style-type: none"> <li>• Has public or private health insurance</li> <li>• Regularly sees primary care doctor</li> <li>• Can afford medication</li> <li>• Transportation</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Medication and/or co-payment waivers</li> <li>• Free service provision</li> <li>• Enhanced access                             <ul style="list-style-type: none"> <li>• Centralized provision</li> <li>• Enhanced referral systems</li> </ul> </li> </ul>
Likely to Receive Rx	<ul style="list-style-type: none"> <li>• Healthcare provider                             <ul style="list-style-type: none"> <li>• Aware of PrEP</li> <li>• Willing to prescribe PrEP</li> <li>• Screens for risk and determines patient eligible</li> </ul> </li> <li>• Patient                             <ul style="list-style-type: none"> <li>• Adequately report behavior eligible for PrEP</li> <li>• PrEP not contraindicated</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Provider education/training</li> <li>• Electronic tools to assess sexual risk and indicate PrEP</li> <li>• Automated systems to minimize provider burden</li> </ul>
Adherence and Efficacy	<ul style="list-style-type: none"> <li>• Side-effects/medication tolerance</li> <li>• Risk compensation</li> <li>• Dosing schedules</li> <li>• Long-term adherence and PrEP continuation</li> </ul>	<ul style="list-style-type: none"> <li>• Counseling                             <ul style="list-style-type: none"> <li>• Medication adherence</li> <li>• Sexual risk reduction</li> </ul> </li> <li>• Home support systems to minimize patient testing burden</li> <li>• Electronic adherence reminders/support</li> </ul>

Colleen F. Kelley et al. Clin Infect Dis. 2015;61:1590-1597



# PrEP Locator Find Your Provider

- About Us
- Locator Data
- FAQ
- Add Provider
- Add Locator To Your Site
- Contact

Chicago

- PrEP for uninsured
- PrEP access assistance

**Northwestern Medical Group**  
 1460 N. Halsted Street  
 5th Floor  
 Chicago, IL 60642  
 312-926-3627  
**Distance from your location:** 1 mile

**Planned Parenthood of Illinois**  
 1152 N. Milwaukee  
 Chicago, IL 60642  
 773-252-2240  
**Distance from your location:** 0.9 miles


**Seton Family Health Center**  
 711 W. North Avenue  
 Chicago, IL 60610  
 312-280-0996  
**Distance from your location:** 1.2 miles

**Planned Parenthood of Illinois**  
 1200 N. LaSalle  
 Chicago, IL 60610  
 312-266-1033  
**Distance from your location:** 1.2 miles

**Rush University Medical Center**  
 600 S. Paulina  
 Suite 140-143  
 Chicago, IL 60612  
 312-942-5865  
**Distance from your location:** 1.7 miles

**Rush University Medical Center Specialty**

- [Add PrEP Locator to Your Site](#)
- [Suggest a provider for the directory](#)



[Suggest A Provider](#) | [Privacy Policy](#) | [Terms of Use](#)

# HealthMindr: A comprehensive HIV prevention platform for MSM








Figure A18. PrEP self-assessment.




Figure A20. PrEP self-assessment.



Figure A21. PrEP self-assessment.






Figure A26. PrEP self-assessment result recommend talking to a doctor about PrEP




Figure A27. PrEP provider locations map.




Figure A28. PrEP provider locations list.




# Participant Demographics


Characteristic	Total (n=121)		Atlanta (n=72)		Seattle (n=49)	
	No.	%	No.	%	No.	%
Age	31	(18-66)	31	(18-66)	30	(18-56)
Race/Ethnicity						
White/Caucasian	62	51	34	47	28	57
Black/African American	25	21	24	33	1	2
Hispanic	10	8	3	4	7	14
Asian/Pacific Islander	13	11	5	7	8	16
Native American/Alaska Native	1	1	0	0	1	2
Multiracial	10	8	6	8	4	8
Sexual orientation						
Gay/homosexual	104	87	64	89	40	83
Bisexual	14	12	8	11	6	13
Other	2	2	0	0	2	4
Most recent HIV test result						
Unsure	8	7	7	10	1	2
Never tested	18	15	14	20	4	8



# App Pages Accessed by Users



# App Pages Accessed by Users



# Preliminary Evaluation Results (n=99)

- 78% of those reported dissatisfied with current condoms ordered new condoms
- 87% report using the ordered condoms
- 2/3 of test kit orders were not planning on being tested soon
- 50% of users who did not have a testing schedule now do
- 10% of PrEP-eligible men started PrEP



# PrEP starts: HealthMindr Pilot

- 8/80 PrEP eligible started PrEP
- *“I went through and put in my (screener) responses and it basically said ‘Hey maybe you should check out PrEP as an option and by the way here are some places you could go.’ ... I was seen (for PreP) at [provider] within a week ... Easy breezy. (Healthmindr) was the piece that crossed the threshold from inaction to actual action. ... This (Healthmindr) will saves lives, and I can even say maybe my life.” - Pilot participant*



# PrEP at Home

- Need to bring PrEP to scale
- CDC Guidance: at least four follow-up visits per year
- 492,000 US MSM behaviorally eligible for PrEP
- 1,968,000 patient visits per year for clinic-based HIV, STI and creatinine testing
- A home care kit could alleviate the economic burden on patients, providers and the healthcare system



## Sources:

1. US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014. A Clinical Practice Guidelines. Available at: <https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf>.
2. Smith et al 2015; MMWR 64(46);1291-1295




**Standard PrEP  
 Initiation and follow  
 up at 1 and 3 months**



**Subsequent follow-up  
 visit, participant  
 receives kit from  
 central lab**



**Participant uses kit,  
 returns mailer to lab**



**Lab receives kit.  
 Results collated with  
 behavioral survey.**

Participant Test Summary Form		PrEP@ Home
<b>Participant Information</b>		
Participant ID#	0000	E
Name	John Doe	Gender
Date Specimens Collected	6/13/2016	Date Specimens Tested
<b>Section 1: HIV Testing</b>		
HIV	Outlook	Interpretation: This Serivie HIV test
<b>Section 2: Symptomatic Screening for Acute HIV</b>		
Fever, Swollen Glands, Sore Throat, Muscle and Joint Aches and Pains, Fatigue, Rash/Itchiness		Interpretation: No Acute HIV symptoms
<b>Section 3: STI / Chiral / Rectal / Genital</b>		
Syphilis	Chlamydia / Gonorrhea	Interpretation: Genitohygiene practiced tested positive
Chlamydia / Gonorrhea	Chlamydia / Gonorrhea - Abdominal	Interpretation: No symptoms
<b>Section 4: Behavioral Function</b>		
Creatinine Levels		Interpretation: Cr < 1.5 will be normal range
<b>Section 5: Medication Adherence</b>		
Self-Reported Adherence		Interpretation: Did not miss a dose in the past 7 days
<b>Section 6: HIV Behavioral Risk</b>		
Self-Reported Risk Survey		Interpretation: See original consent/assent/IRB for more details on PrEP program
<b>Section 7: Recommendations</b>		
<input type="checkbox"/> Available HIV treatment? <input type="checkbox"/> Being in immediate need for acute HIV testing? <input type="checkbox"/> Call or visit to evaluate side effects.	<input type="checkbox"/> Consider requesting mobile medication adherence counseling. <input type="checkbox"/> Consider requesting mobile risk reduction counseling. <input type="checkbox"/> Other:	

**Results sent to  
 provider**



**Provider can renew RX, or  
 treat or refer to  
 telemedicine counseling as  
 needed**

# PrEP@Home Video

Provider form

Participant Information			
Participant Name	Doe <i>Last</i>	John <i>First</i>	E <i>MI</i>
			 Optimal  Elevated  High
			Date Specimens Collected: 6/13/2016 Date Specimens Tested: 6/17/2016
Participant Initials	<input type="text" value="D"/> <input type="text" value="J"/> <input type="text" value="E"/>		

### Section 1: HIV Testing

HIV	<del>Oraquick</del>		Interpretation: Non-Reactive HIV test
-----	---------------------	--	---------------------------------------

### Section 2: Symptomatic Screening for Acute HIV

Fever, Swollen Glands, Sore Throat, Muscle and Joints Aches and Pains, Fatigue, and Headache		Interpretation: No Acute HIV symptoms
--	--	---------------------------------------

### Section 3: STIs – Oral / Rectal / Genital

Syphilis		Interpretation: Gonorrhea pharyngeal tested positive
Chlamydia / Gonorrhea		
Test type: Syphilis – RPR Chlamydia / Gonorrhea – Abbott <del>RealTime</del>		

### Section 4: Kidney Function

Creatinine Levels		Interpretation: GFR is within the normal range
-------------------	--	--

### Section 5: Medication Adherence


Self-Reported Adherence		Interpretation: Has not missed a dose in the past 7 days
-------------------------	--	--

### Section 6: HIV Behavioral Risk

Self-Reported Risk Survey		Interpretation: Has reported increased <del>condomless sex</del> since last visit with PrEP provider.
---------------------------	--	---

### Section 7: Recommendations



<input checked="" type="checkbox"/>	Bring in immediately for STI treatment.*	<input type="checkbox"/>	Consider requesting telephone medication adherence counseling
<input type="checkbox"/>	Bring in immediately for acute HIV testing <sup>Δ</sup>	<input checked="" type="checkbox"/>	Consider requesting telephone risk reduction counseling
<input type="checkbox"/>	Call or visit to evaluate side effects.	<input type="checkbox"/>	Other: _____



- Provider: “Anything to help me do PrEP well, to be able to provide the services, I think it’s fantastic.”
- Provider: “I think it’s great. I think that we have to decentralize ... particularly for folks who don’t have good experiences or access to providers ... the idea that you have to come into a visit in order to get some of the medical care particularly around PrEP where (patients are) usually generally young healthy folks is not necessary.”
- Patient: “I think it’s pretty useful especially for the STI testing ... I would highly encourage this to be out in the world. I think it will help a lot.”
- 4/15 patients rated themselves as more likely to remain on PrEP if a home kit was available.

# Pilot testing

- Provider: “Anything to help me do PrEP well, to be able to provide the services, I think it’s fantastic.”
- Provider: “I think it’s great. I think that we have to decentralize ... particularly for folks who don’t have good experiences or access to providers ... the idea that you have to come into a visit in order to get some of the medical care particularly around PrEP where (patients are) usually generally young healthy folks is not necessary.”
- Patient: “ I think it’s pretty useful especially for the STI testing ... I would highly encourage this to be out in the world. I think it will help a lot.”
- 4/15 patients rated themselves as more likely to remain on PrEP if a home kit was available.



# Next Steps

- PrEP Strategic Summit – January 2016
- For the field
  - Approvals (?) and consensus on adolescent PrEP
- For Emory team
  - Remote PrEP provision – mobile app, telemedicine
  - Further study of home monitoring kits
  - Optimization of PrEP Continuum in cohort of young black MSM in Atlanta

# Team and funders

- Colleagues

- Hannah Cooper
- Carlos del Rio
- Ralph DiClemente
- Paula Frew
- Colleen F. Kelley
- Mark Mulligan
- John Peterson (GSU)
- Eli Rosenberg
- Laura F. Salazar (GSU)
- Travis Sanchez
- Gina Wingood
- Aaron Siegler

- Colleagues

- Steve Goodreau
- Rob Brookmeyer
- Chris Beyrer
- Rob Stephenson
- Joanne Stekler
- Rob Driggers
- Adam Vaughan

- Dedicated team of staff:

- Project coordinators
- Recruiters
- Event staff
- Retention specialists
- Data managers, analysts

**Supported by**

**National Institutes of Health #:**

- R01-MH085600
- R01-HD067111
- R21-MH103187
- R01-AI094575
- P30-AI050409

**MAC AIDS Fund  
Gilead Sciences**